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Abstract: Mucositis, also referred to as mucosal barrier
injury, is one of the most debilitating side effects of
radiotherapy and chemotherapy treatment. Clinically,
mucositis is associated with pain, bacteremia, and
malnutrition. Furthermore, mucositis is a frequent reason
to postpone chemotherapy treatment, ultimately leading
towards a higher mortality in cancer patients. According
to the model introduced by Sonis, both inflammation and
apoptosis of the mucosal barrier result in its discontinuity,
thereby promoting bacterial translocation. According to
this five-phase model, the intestinal microbiota plays no
role in the pathophysiology of mucositis. However,
research has implicated a prominent role for the
commensal intestinal microbiota in the development of
several inflammatory diseases like inflammatory bowel
disease, pouchitis, and radiotherapy-induced diarrhea.
Furthermore, chemotherapeutics have a detrimental
effect on the intestinal microbial composition (strongly
decreasing the numbers of anaerobic bacteria), coinciding
in time with the development of chemotherapy-induced
mucositis. We hypothesize that the commensal intestinal
microbiota might play a pivotal role in chemotherapy-
induced mucositis. In this review, we propose and discuss
five pathways in the development of mucositis that are
potentially influenced by the commensal intestinal
microbiota: 1) the inflammatory process and oxidative
stress, 2) intestinal permeability, 3) the composition of the
mucus layer, 4) the resistance to harmful stimuli and
epithelial repair mechanisms, and 5) the activation and
release of immune effector molecules. Via these pathways,
the commensal intestinal microbiota might influence all
phases in the Sonis model of the pathogenesis of
mucositis. Further research is needed to show the clinical
relevance of restoring dysbiosis, thereby possibly decreas-
ing the degree of intestinal mucositis.
Introduction
Mucositis, also referred to as mucosal barrier injury, is one of
the most debilitating side effects of radiotherapy and chemother-
apy treatment [1]. It is characterized by both inflammation and
cell loss in the epithelial barrier lining the gastrointestinal tract
[2,3]. Clinically, mucositis is associated with bacteremia, malnu-
trition, the use of total parenteral nutrition, and an increment in
the use of intravenous analgesics. These complications all lead to
longer hospitalizations and increasing health care costs. Moreover,
mucositis is a frequent reason for reducing the dosages of
chemotherapeutics or to postpone chemotherapy treatment,
ultimately leading towards a higher mortality in cancer patients
[2,4].
Historically, research has focused on oral mucositis. More
recently, attention has been drawn towards the pathophysiology
and clinical symptoms of intestinal mucositis, which is character-
ized by symptoms like nausea, bloating, vomiting, abdominal pain,
and severe diarrhea [5,6].
According to the model introduced by Sonis, five phases are
important in the pathophysiology of mucositis: (1) the formation of
reactive oxygen species leading to the activation of nuclear factor
kappa B (NFkB) during the initiation phase, (2) the induction of
messenger molecules such as tumor necrosis factor alpha (TNFa),
resulting in treatment-related tissue inflammation and apoptosis
during the upregulation/message generation phase, (3) the
amplification of messenger molecules in the amplification/
signaling phase, leading to more inflammation and apoptosis, (4)
discontinuity of the epithelial barrier resulting from apoptosis
during the ulcerative phase, thereby promoting bacterial translo-
cation, and (5) a spontaneous healing phase, characterized by cell
proliferation [3]. According to this five-phase model, the intestinal
microbiota plays no role in the pathophysiology of mucositis.
However, research has implicated a role for the commensal
intestinal microbiota in several local and systemic inflammatory
diseases like inflammatory bowel disease, pouchitis, radiotherapy-
induced diarrhea, atopic disease, obesity, and diabetes [7–11].
Recent studies have also shown that both chemotherapeutics and
(prophylactically used) antibiotics do have an effect on intestinal
microbial composition [12–14]. Moreover, the effects of the
changing commensal intestinal microbiota on the development
and severity of mucositis are being unravelled. Research has
shown that bacteria play a role in the metabolism of certain
chemotherapeutics. The outgrowth of these bacteria might lead to
the formation of active toxic metabolites of the chemotherapeutic
drug, which directly affects the progression of intestinal mucositis
[13]. However, the commensal intestinal microbiota might also
have beneficial effects on the development of intestinal mucositis,
as the mere presence of resident intestinal bacteria might offer
protection against its development. In this review, we propose and
discuss five pathways in the development of mucositis that are
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potentially influenced by the commensal intestinal microbiota: 1)
the inflammatory process and oxidative stress, 2) intestinal
permeability, 3) the composition of the mucus layer, 4) the
resistance towards harmful stimuli and epithelial repair mecha-
nisms, and 5) the activation and release of immune effector
molecules (Figures 1 and 2).
Host–Microbe Interaction
A detailed review of the communication pathways between the
intestinal microbiota and the human host is beyond the scope of
this article and this communication is therefore only shortly
reviewed.
The epithelial barrier lining the gastrointestinal tract is
composed of a single layer of epithelial cells intertwined by tight
junctions [15]. These epithelial cells have two important functions.
Firstly, they form a mechanical barrier separating the inside of the
human body from the outside world. Secondly, they are essential
in the communication between the human body and the intestinal
microbiota [16–18].
An important aspect of these two functions of the epithelial cells
is the dual mucus layer at the apical side of the epithelial cells
[19,20]. The inner layer strengthens the epithelial barrier, whereas
the loose outer layer is proposed to be important in the
communication between epithelial cells and microbiota [20,21].
With respect to the communication between microbes and the
gut, two groups of receptors are thought to be important in the
communication between the human body and the resident
microbiota: the Toll-like receptor (TLR) family and the nucleotide
oligomerisation domain (NOD) receptor family [22–25]. Both
groups of receptors play an important role in the genesis and
modulation of the inflammatory response. The TLRs are present
at the outer membrane of the epithelial cells. Bacteria are
recognized by the extracellularly located part of TLRs, leading to
activation of NFkB [23,25]. In turn, activation of NFkB results in
the development of an inflammatory response. So far, multiple
Figure 1. The epithelial barrier is comprised of a single layer of epithelial cells intertwined by tight junctions. The mechanical barrier is
increased further by a mucus layer. Binding of bacteria to TLRs present on epithelial cells results in the activation of NFkB, ultimately resulting in the
release of pro-inflammatory and anti-inflammatory cytokines. After phagocytosis, bacterial products are internalized and then are recognized by
receptors of the NOD family (NLRs), resulting in the modulation of the inflammatory response. Dendritic cells are capable of internalizing bacteria
sampled from the lumen, after which bacteria are presented to immune effector cells. HSPs, heat shock proteins; NLR, NOD-like receptor; sIgA,
secretory immunoglobulin A; TLR, Toll-like receptor.
doi:10.1371/journal.ppat.1000879.g001
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members of the TLR family have been described in mammals.
The most extensively researched receptors are TLR-2, TLR-3,
TLR-4, TLR-5, and TLR-9 [16,23,26–32]. TLR-2 is activated by
peptidoglycan, a part of the cell wall of gram-positive bacteria,
whereas TLR-4 is activated by lipopolysaccharide (LPS), a
substance of gram-negative microorganisms. TLR-3 is activated
by viral DNA, TLR-9 is activated by bacterial DNA, and TLR-5 is
activated by the protein flagellin, present in flagellated bacteria.
After binding to TLRs, bacteria are processed and bacterial parts
are transported intracellularly. Here they bind to receptors of the
NOD family. It is believed that activation of NOD receptors
modulates the inflammatory response activated by TLR binding
[22]. This theory is supported by the fact that NOD2/2 mice are
profoundly susceptible to intestinal inflammation [33,34]. More-
over, mutations in NOD2 are associated with the development of
Crohn’s disease in humans [35–37].
Not only epithelial cells, but also local dendritic cells are thought
to play a role in the initiation and/or modulation of intestinal
inflammation and, in addition, in the induction of tolerance [38–
40]. Dendritic cells sample bacteria from the intestinal lumen,
after which these bacteria are transported to the local lymph
nodes. Here, the bacteria are presented to immune cells, whose
activation can result in the activation of the innate and adaptive
immune system. Why certain microbial stimuli result in tolerance
where others induce an inflammatory response is still largely
unknown.
Pathways Describing the Role of Commensal
Intestinal Microbiota in Mucositis
1) Influencing the Inflammatory Process and Modulating
Oxidative Stress
The healthy human intestine is characterized by a state of low-
grade inflammation. The resident microbiota guarantees a constant
exposure to TLR ligands such as peptidoglycan, LPS, and bacterial
DNA. This ensures a continuous basal activation of downstream
signaling pathways, resulting in low-grade physiological inflamma-
tion [25,27]. Paradoxically, commensal bacteria are also capable of
suppressing more severe inflammatory responses, and their
disappearance may even result in incremental inflammation
[41–46]. For example, Bacteroides thetaiotaomicron and Bifidobacterium
infantis both decrease NFkB activation [43,47], leading to a decrease
in endotoxin levels and plasma interleukin (IL)-6 levels [45]. The
Clostridium XIVa group has been proposed to attenuate intestinal
inflammation by exerting an effect on polyamine secretion, which in
turn regulates the expression of TLR-2 [28,48].
Figure 2. The resident microbiota interferes in the process of mucositis. Depicted are five possible ways in which intestinal bacteria can
attenuate or aggrevate mucositis: 1) influencing the inflammatory process, 2) influencing intestinal permeability, 3) influencing the composition of
the mucus layer, 4) influencing resistance to harmful stimuli and enhancing epithelial repair, and finally, 5) the activation and release of immune
effector molecules.
doi:10.1371/journal.ppat.1000879.g002
PLoS Pathogens | www.plospathogens.org 3 May 2010 | Volume 6 | Issue 5 | e1000879
Bacteria or bacterial parts, as well as their secreted products,
relieve inflammatory symptoms. For example, Faecalibacterium
prausnitzii secretes a substance capable of decreasing NFkB
activation. This so far unidentified substance induces the
production of the anti-inflammatory IL-10, thereby attenuating
inflammation. B. infantis also secretes an unidentified product that
attenuates colitis in mice [46,49]. Several intestinal bacteria
produce short chain fatty acids (SCFAs), with butyrate being the
most thoroughly investigated. Butyrate is produced by F. prausnitzii
and Clostridium XIVa and has been shown to have profound anti-
inflammatory effects [50–54]. Substitution of butyrate attenuates
inflammatory symptoms in (diversion) colitis and chemotherapy-
induced mucositis in vivo in mice [46,55–58]. Moreover, butyrate
not only attenuates inflammation, but also reduces intestinal
permeability and stimulates the activation of immune effector
molecules.
In short, multiple intestinal bacteria are capable of decreasing
NFkB activation, resulting in a diminished production of
inflammatory cytokines. The exact nature and relevance of the
relationship between chemotherapy-induced mucositis, inflamma-
tion, and intestinal microbiota is subject to ongoing research.
2) Influencing Intestinal Permeability
Intestinal permeability increases after chemotherapy treatment,
and has been shown to be one of the hallmarks of the third and
fourth phases of mucositis as reported by Sonis [2,3,6]. One of the
mechanisms resulting in a chemotherapy-induced increase in
permeability is probably villous atrophy. Atrophy leads to an
increase of intestinal permeability, as has been shown both in vivo
and in vitro [59]. However, the resident intestinal microbiota has
also been proposed to influence intestinal permeability [26,60].
Indeed, several commensal bacteria have been shown to improve
the epithelial barrier function both in vitro and in vivo, although
not all in vivo studies were able to confirm these improvements
[59,61–65]. For example, TLR-2 ligands stimulate the phosphor-
ylation of protein kinase C, leading to a decrease in intestinal
permeability [26]. This decrease in permeability is proposed to be
the result of changes in tight junctions. Administration of
bifidobacteria is associated with an enhanced expression of
proteins forming tight junctions [49], and has been shown to
decrease intestinal permeability [64]. Both bifidobacteria and
lactobacilli have been shown to increase tight junction protein
expression and restore intestinal permeability [66–68].
Another factor contributing to attenuating intestinal permeabil-
ity is the bacterial induction of heat shock proteins (HSPs). These
HSPs are thought to preserve the viability of epithelial cells in
stress conditions [69–71], thereby reducing intestinal permeability.
Finally, the bacterial production of SCFAs is associated with a
reduction in intestinal permeability. This effect of SCFAs is also
proposed to be mediated by an increase in epithelial cell viability
[52,58,72].
Epithelial cell loss is a hallmark of the third phase of the five-
phase mucositis model, eventually resulting in an increased
permeability. The commensal intestinal microbiota attenuates
cellular atrophy and increases tight junction strength. Therefore,
we propose that changes in the commensal intestinal microbiota
influence the third phase of mucositis. This way, the commensal
intestinal microbiota might influence the eventual severity of
mucositis encountered in the ulcerative phase.
3) Influencing the Composition of the Mucus Layer
As mentioned before, the mucus layer covering the intestinal
epithelium strengthens the mechanical epithelial barrier. The
protective mucus layer is comprised of glycoproteins, trefoil
factors, and mucins. These mucins are produced by goblet cells,
which are specialized epithelial cells [73]. The composition of the
mucus layer is important in the protection against bacterial
infections and inflammation. For example, it has been shown that
mucin type 2 knockout mice develop severe colitis after harmful
stimuli, in contrast to mice capable of producing mucin 2.
Furthermore, in animals lacking mucin 2, bacteria are detected
deep down in the normally sterile crypts of the intestine [20,74].
The commensal intestinal microbiota is proposed to play a role
in the maintenance of the mucus layer. Indeed, the absence of
these intestinal microbiota is associated with a decrease in goblet
cells, which are also smaller in size [75]. Furthermore, the
thickness of the mucus layer is decreased in animals devoid of
intestinal microbiota.
The genes encoding mucins are directly regulated by bacteria
and their products [76–78], and in response to intestinal microbes
and/or their secreted products the secretion of mucus increases
[76,79]. For example, both Lactobacillus rhamnosus Gorbach and
Goldin (GG) and Lactobacillus plantarum increase the expression of
MUC-2 and MUC-3 genes, and Lactobacillus acidophilus upregulates
MUC-2 gene expression [77,80]. Furthermore, bacteria producing
butyrate are thought to play a role in the composition of the mucus
layer, as butyrate is capable of increasing mucin synthesis as well
[52].
The commensal resident microbiota not only interferes with the
expression of MUC genes, but also interferes with the expression
and/or activity of cell glycosyltransferases. These enzymes induce
changes in the carbohydrate repertoire of mucins, which might
change their efficacy in bacterial defense [81,82].
Thus, the intestinal microbiota influences the composition of the
mucus layer covering the epithelium, thereby increasing the
strength of the epithelial barrier. A strengthened barrier decreases
the risk of bacterial translocation, thereby possibly attenuating
inflammation present in the ulcerative phase of the Sonis mucositis
model.
4) Influencing Resistance to Harmful Stimuli and
Influencing Epithelial Repair
The commensal intestinal microbiota contributes to epithelial
repair. In germ-free animals, the mitotic index and cell turnover of
epithelial cells are lower as compared to normally colonized
animals [83,84]. Moreover, the transit time of epithelial cells
migrating towards the top of the intestinal villi is prolonged [85].
These changes result in a retarded renewal, i.e., a retarded repair,
of the intestinal epithelium.
Bacterial induction of NFkB not only controls the physiological
state of low-grade inflammation in the intestine, it also stimulates
the repair of, for example, mechanical-induced epithelial damage
[86]. The importance of bacterial ligands in this process is shown
in TLR-42/2 epithelial cells. These cells, which are not capable
of recognizing the resident microbiota, exhibit severe repair
defects in response to harmful chemical stimuli. This is probably
due to a reduced capacity of NFkB-induced cytoprotective factors
such as HSPs and IL-6 [25,29]. When TLR ligands were
administered to germ-free mice, this was sufficient to protect
them against artificially induced colitis [25].
Bacteria acting as TLR ligands are not the only ones that play
an important role in increasing the resistance towards harmful
stimuli and enhancing epithelial repair. Again, butyrate plays an
important role. Butyrate stimulates the migration of epithelial cells,
thereby enhancing mucosal healing [52,72]. Other bacterial
products, such as the peptides secreted by L. rhamnosus GG, have
been shown to inhibit cytokine-induced apoptosis and promote cell
growth, thereby also enhancing mucosal repair [87].
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Therefore, we again propose that the commensal intestinal
microbiota might attenuate the epithelial damage in the third
phase of mucositis. As the commensal intestinal microbiota
stimulates epithelial repair mechanisms, it can be hypothesized
that the microbiota also attenuates mucositis by influencing the
healing phase of mucositis.
5) Influencing the Production and Release of Immune
Effector Molecules
The commensal intestinal microbiota regulates the expression
and release of immune effector molecules. These molecules are
pivotal for maintaining intestinal homeostasis [27,88–90]. For
example, if the contact between microbiota and intestinal
epithelium suddenly increases, the expression of RegIIIc increases.
This C-type lectin has antimicrobial activity and limits bacterial
translocation. Furthermore, it maintains intestinal integrity and
homeostasis [89,90].
Another immune effector molecule influenced by the resident
microbiota is immunoglobulin A (IgA). IgA is produced by
mucosa-associated immune effector cells [81,90,91]. Intestinal
microbiota is capable of regulating the expression of IgA, which in
turn regulates the composition of the intestinal microbiota. For
example, suppletion of bifidobacteria is associated with an increase
in the expression of secretory IgA [92].
Both live bacteria and their products are capable of upregulat-
ing immune effector molecules. For example, SCFAs such as
butyrate regulate the production of cathelicidins, which exhibit
broad-spectrum anti-bacterial activity against potential pathogens
[93].
By influencing the expression and release of immune effector
molecules, the commensal intestinal microbiota regulates itself and
maintains homeostasis in the intestinal tract. In the end, this will
positively influence all five phases described in Sonis’s mucositis
model.
Conclusion; an Extended Five-Phase Model for
Mucositis
Although the protective role of commensal intestinal bacteria in
human disease is increasingly being appreciated, research
concerning the relationship between intestinal bacteria and
chemotherapy-induced mucositis is still scarce. Most studies that
investigate the role of bacteria in human disease have focused on
inflammatory bowel disease, which is caused by a chronic
inflammatory process instead of the acute damage induced by
chemotherapeutics.
In the model introduced by Sonis to explain the pathogenesis of
radiotherapy-induced and chemotherapy-induced mucositis, the
resident intestinal microbiota played no role [3]. However,
recently it has been shown that chemotherapy treatment is
associated with a decrease in the number of anaerobic bacteria
and a decrease in microbial diversity [14,94]. Furthermore, the
resident intestinal bacteria have been shown to play a role in
radiotherapy-induced diarrhea [10]. Moreover, research has
shown that a decreasing microbial diversity coincides in time with
the development of severe chemotherapy-induced mucositis (M.
van Vliet et al., unpublished data). We hypothesize that the
commensal intestinal microbiota might play a pivotal role in both
radiotherapy-induced and chemotherapy-induced mucositis when
the intestine is irradiated or when chemotherapeutics are used that
deregulate intestinal microbial homeostasis, as the disappearance
of the intestinal microbiota will minimize their protection of
enterocytes against harmful stimuli. Further research is needed to
show whether the commensal intestinal bacteria should be
incorporated as a meaningful factor in Sonis’s five-phase model
for mucositis. Theoretically, the commensal intestinal microbiota
could influence all phases of the pathogenesis of mucositis: the
initiation phase, the phase of upregulation and message genera-
tion, the phase of amplification and signalling, the ulcerative
phase, and the healing phase.
Further research will also have to show the clinical relevance of
restoring dysbiosis, thereby possibly decreasing the degree of
intestinal mucositis. This would not only increase the quality of life
of patients, but could also positively influence treatment intensity,
probably decreasing the morbidity and mortality of cancer
patients. Completely restoring dysbiosis might be a clinical
problem, since whole live bacteria used as probiotics have already
been described as causing invasive infections in immunocompro-
mised patients and were associated with increased mortality in
patients with severe pancreatitis [95–98]. However, it has been
shown that substitution of bacterial parts instead of whole live
bacteria might be sufficient to attenuate local and systemic
inflammation without the risk of invasive infections [30,99,100].
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